For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Sandoz Group AGSDZ SW · Health Care · CHF Current priceCHF 81.50as of Nov 19, 2026 Summary
Analyst consensusStrong Buy 3Buy 4Hold 7Sell 1Strong Sell 116 analysts 3-year price (CHF)Factor profileMulti-factor score 36 / 100 Market data
Business descriptionSandoz Group AG is a global leader in the development, manufacturing, and marketing of generic and biosimilar medicines, spun off from Novartis in 2023. The company holds a prominent position in generic antibiotics, supported by a vertically integrated penicillin network in Europe, and pioneered the biosimilar market. Competitive moatSandoz benefits from its deep pipeline covering approximately 59% of upcoming biologics loss of exclusivity (LOE) and 65% of small molecule LOE over the next decade. Its substantial investment in vertical integration, including a $1.1B expansion of its European biosimilar hub in Slovenia, provides strong supply chain control and cost advantages. Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Aug 10, 2026
Current price: CHF 81.50 · Nov 19, 2026· CHF
CFRA Ratingbuy
TBI Multi Score36
Theme Exposure
Related Peers
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart
SDZ.SW80.40CHF+50.7%
Daily closes · Yahoo Finance · TradingView does not carry this exchange
Business description
Sandoz Group AG is a global leader in the development, manufacturing, and marketing of generic and biosimilar medicines, spun off from Novartis in 2023. The company holds a prominent position in generic antibiotics, supported by a vertically integrated penicillin network in Europe, and pioneered the biosimilar market.
Competitive moat
Sandoz benefits from its deep pipeline covering approximately 59% of upcoming biologics loss of exclusivity (LOE) and 65% of small molecule LOE over the next decade. Its substantial investment in vertical integration, including a $1.1B expansion of its European biosimilar hub in Slovenia, provides strong supply chain control and cost advantages.
Recent developments
- 2026-08-05: Q2 2026 sales acceleration was driven by the successful June 2025 launches of Wyost and Jubbonti in North America, which captured 54% and 64% of the biosimilar market respectively.
- 2026-07-22: Proposed U.S. generic tariffs highlight manufacturing exposure, as the U.S. accounts for ~17% of group sales while Sandoz's footprint is predominantly European. Management is in active dialogue with the U.S. administration.
- 2026-06-29: FDA accepted two applications for generic versions of tirzepatide (Eli Lilly's Zepbound/Mounjaro), positioning Sandoz as a potential first-to-market generic entrant upon patent expiry.
- 2026: Reached a settlement to resolve all pending class actions and governmental claims in legacy U.S. generic antitrust litigation involving $400M spread over 7 years, removing a significant overhang.
Investment risks / red flags
- ⚠️ Proposed U.S. generic tariffs could weigh on profitability given Sandoz's reliance on its European manufacturing hub.
- Pipeline execution remains a major risk, where any delay to product launches could affect future growth.
- Intense competition and continuous pricing pressure in the generics market.
Market Data
Source: mkts.io · Nov 19, 2026, 06:00 UTC
Key Metrics
P/E (TTM)69.66
P/E (Fwd)21.21
Dividend0.96%
Beta0.40
52W HighCHF 86.90
52W LowCHF 52.54
Analyst Consensus
3
4
7
Strong Buy3Buy4Hold7Sell1Strong Sell116 analysts
Consensus TargetCHF 81.75
+0.3% upside
Calendar Events
Ex-DividendApr 13, 2026
Dividend DateApr 23, 2025
Financials
RevenueCHF 11.68B
Rev Growth9.90%
Earnings Growth-71.30%
Gross Margin47.79%
Op Margin9.27%
Profit Margin5.53%
EBITDACHF 1.57B
ROA3.05%
ROE7.25%
Rev/ShareCHF 26.94
Total CashCHF 2.27B
Total DebtCHF 6.20B
D/E Ratio68.92
Free Cash FlowCHF 1.37B
Op Cash FlowCHF 1.94B
Current Ratio1.05
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | — | CHF 3.00B |
| +1q | — | CHF 0.00 |
| 0y | 4.18 | CHF 11.98B |
| +1y | 4.66 | CHF 12.66B |
Earnings
Annual
2022
Rev CHF 0.00Earn CHF 848.00M
2023
Rev CHF 9.65BEarn CHF 77.00M
2024
Rev CHF 10.36BEarn CHF 0.00
2025
Rev CHF 11.09BEarn CHF 914.00M
